Will Axtell

Partner

Will is a partner in the corporate team, specialising in buying and selling companies, fundraisings, spin-outs and other corporate law matters. He has particular expertise in the technology sector and spent many years advising fast-growing tech companies.

Life sciences is another area of focus and Will has acted on numerous Oxford University spin-outs, including Vaccitech, now Barinthus Biotherapeutics, the co-inventor of the Oxford/AstraZeneca vaccine. Will’s clients include start-ups and high-growth companies as well as high net worth individuals and successful entrepreneurs. He particularly enjoys helping entrepreneurs achieve a successful exit to a larger buyer, either trade or private equity.

I have a commercial approach and focus on what is important to my clients and aim to build strong, long-lasting relationships. A transaction can often be an intense and demanding experience, and I enjoy helping clients navigate this often bumpy landscape towards a successful outcome.

Will Axtell, Partner

The Legal 500 lists Will as a leading partner for corporate law. He joined Penningtons Manches Cooper in 2014 from another leading UK law firm. Earlier in his career, he spent several years as an in-house corporate lawyer with Vodafone, working mainly on high-profile mergers and acquisitions. He trained, qualified and spent several years at a Magic-Circle firm.

Recent work highlights

UK/US cross-border deal

Advising on the sale of Titian Software to US-based Battery Ventures, an important cross-border technology transaction.

Life sciences transaction

Advising the shareholders of oligonucleotides maker ATDBio on its c£45 million sale to NASDAQ Stockholm listed Biotage AB.

Marina technology transaction

Acting for the shareholders of leading cloud-based marina management system Harbour Assist on its acquisition by leading software and payment solution provider ClearCourse

Oxford University spin-out

Advising Barinthus Biotherapeutics, the co-creator of the Oxford/AstraZeneca vaccine, on its spin-out from the University of Oxford and its £10 million funding round.

Imperial College spin-out

Advising Mint Neurotechnologies, pioneers of scalable semiconductor technology for minimally invasive neural implants, on its spinout from Imperial College and its funding round.

UK/US cross-border transaction

Acting for the shareholders of Global Design Innovation Limited, a provider of digital and software services in the energy sector, on its acquisition by US-based Oceaneering International.

Battery technology sale

Acting for the shareholders of OXLiD, an Oxford based lithium-sulfur battery technology developer, on its acquisition by AIM-listed Anglo-Australian battery innovator, Gelion.

UK/US life sciences deal

Acting for the shareholders of Delta Hat Limited, a leading provider of analysis and health economic modelling to the life sciences and healthcare sectors, on its acquisition by Petauri, a New York-based private equity firm.

UK/US cross border acquisition

Acting for US-based Smithers on its acquisition of UK-based ResChem Analytical, specialists in pesticide residue analysis, to expand its capacity in the agrochemical sector.

Battery technology sale

Acting for the shareholders of OXLiD, an Oxford based lithium-sulfur battery technology developer, on its acquisition by AIM-listed Anglo-Australian battery innovator, Gelion.

UK/US life sciences deal

Acting for the shareholders of Delta Hat Limited, a leading provider of analysis and health economic modelling to the life sciences and healthcare sectors, on its acquisition by Petauri, a New York-based private equity firm.

UK/US cross border acquisition

Acting for US-based Smithers on its acquisition of UK-based ResChem Analytical, specialists in pesticide residue analysis, to expand its capacity in the agrochemical sector.

Related news and insights